Sustained Virological Response (SVR)Rate of Pegasys Plus Ribavirin in Patients With Chronic Hepatitis C
Status:
Terminated
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of PEGASYS® (peginterferon alfa-2a 40KD)
plus Robatrol® (ribavirin) combination therapy given for 36 weeks versus 48 weeks on the
clearance of HCV viremia 24 weeks after treatment end